Cynata Therapeutics Ltd
F:51S
Cynata Therapeutics Ltd
F:51S
Price:
0.0005
EUR
Market Closed
Market Cap:
€90.3k
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cynata Therapeutics Ltd
F:51S
|
AU |
|
K
|
Kobayashi Pharmaceutical Co Ltd
XMUN:KOY
|
JP |
|
Aegis Brands Inc
F:6I9
|
CA |
|
C
|
Cognyte Software Ltd
F:81M
|
IL |
|
V
|
Verde Agritech PLC
F:AZA
|
UK |
|
F
|
Far East Orchard Ltd
F:O5P
|
SG |
|
H
|
Havila Shipping ASA
LSE:0LGI
|
NO |
|
F
|
Freegold Ventures Ltd
F:FR4N
|
CA |
|
FendX Technologies Inc
OTC:FDXTD
|
CA |
|
O
|
Oaktree Specialty Lending Corp
F:FFC
|
US |
|
P
|
Pan African Resources PLC
F:RTZ
|
UK |
|
D
|
Dometic Group AB (publ)
F:D00
|
SE |
|
H
|
HELLENiQ ENERGY Holdings SA
SWB:HLPN
|
GR |
|
M
|
Morphic Holding Inc
F:31Y
|
US |
|
Decmil Group Ltd
ASX:DCG
|
AU |
|
Compagnie du Bois Sauvage SA
F:C5S
|
BE |
|
ImExHS Ltd
ASX:IME
|
AU |
|
Baumot Group AG
F:TINC
|
DE |
Why do you have more estimates than other sites?
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is 51S's stock price target?
Not Available
51S does not have any price targets made by Wall Street professionals.
What is the Revenue forecast for Cynata Therapeutics Ltd?
Projected CAGR
123%
123%
Over the last 13 years, the compound annual growth rate for Revenue has been -3%. The projected CAGR for the next 3 years is 123%.
